CN117030878A - Stable free amino acid underivatization detection method and application thereof - Google Patents
Stable free amino acid underivatization detection method and application thereof Download PDFInfo
- Publication number
- CN117030878A CN117030878A CN202310972108.6A CN202310972108A CN117030878A CN 117030878 A CN117030878 A CN 117030878A CN 202310972108 A CN202310972108 A CN 202310972108A CN 117030878 A CN117030878 A CN 117030878A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- sample
- solution
- volume fraction
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 68
- 238000001514 detection method Methods 0.000 title claims abstract description 51
- 229940024606 amino acid Drugs 0.000 claims abstract description 62
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940009976 deoxycholate Drugs 0.000 claims abstract description 24
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 24
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 17
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 14
- 238000001212 derivatisation Methods 0.000 claims abstract description 13
- 229960000310 isoleucine Drugs 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims abstract description 7
- 238000005070 sampling Methods 0.000 claims abstract description 4
- 235000001014 amino acid Nutrition 0.000 claims description 59
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 32
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 238000010828 elution Methods 0.000 claims description 16
- 229960003136 leucine Drugs 0.000 claims description 15
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 239000011550 stock solution Substances 0.000 claims description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 238000004811 liquid chromatography Methods 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 7
- 239000012086 standard solution Substances 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 239000012224 working solution Substances 0.000 claims description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229960004452 methionine Drugs 0.000 claims description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-HLTLGYGQSA-N (2s)-2-amino-3-(2,4,5,6,7-pentadeuterio-1h-indol-3-yl)propanoic acid Chemical compound [2H]C1=C([2H])C([2H])=C2C(C[C@H](N)C(O)=O)=C([2H])NC2=C1[2H] QIVBCDIJIAJPQS-HLTLGYGQSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- 229960002898 threonine Drugs 0.000 claims description 4
- 229960004295 valine Drugs 0.000 claims description 4
- ZDXPYRJPNDTMRX-NKXUJHECSA-N (2s)-2,5-diamino-2,3,3,4,4-pentadeuterio-5-oxopentanoic acid Chemical compound NC(=O)C([2H])([2H])C([2H])([2H])[C@]([2H])(N)C(O)=O ZDXPYRJPNDTMRX-NKXUJHECSA-N 0.000 claims description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 3
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 229930182816 L-glutamine Natural products 0.000 claims description 3
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- 229960002743 glutamine Drugs 0.000 claims description 3
- 229960002449 glycine Drugs 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 3
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- MMROPYXLFHLHJY-UHFFFAOYSA-N [NH4+].CC#N.OC=O.[O-]C=O Chemical compound [NH4+].CC#N.OC=O.[O-]C=O MMROPYXLFHLHJY-UHFFFAOYSA-N 0.000 claims description 2
- ADCGAPKUMAQOLJ-UHFFFAOYSA-N azane;formic acid Chemical compound N.OC=O.OC=O ADCGAPKUMAQOLJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 abstract description 14
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 13
- 210000002381 plasma Anatomy 0.000 abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract description 9
- 230000006920 protein precipitation Effects 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 40
- 239000000523 sample Substances 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 238000005457 optimization Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000012488 sample solution Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- -1 BEH Amide Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 150000002519 isoleucine derivatives Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012490 blank solution Substances 0.000 description 2
- ABDBNWQRPYOPDF-UHFFFAOYSA-N carbonofluoridic acid Chemical compound OC(F)=O ABDBNWQRPYOPDF-UHFFFAOYSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a stable non-derivatization detection method of free amino acid and application thereof, wherein the detection method comprises the following steps: mixing a sample to be detected with deoxycholate, trichloroacetic acid and an internal standard, centrifuging, taking supernatant, sampling, detecting by liquid chromatography-mass spectrometry, and calculating the content of free amino acid in the sample to be detected according to the detection result and a standard curve. The detection method provided by the invention can be used for simultaneously measuring 21 amino acids in blood plasma under the condition of not using an ion pair reagent, the sample consumption is small, the protein precipitation is complete, the chromatographic column loss caused by the sample can be reduced, the stability is high, the accuracy is high, the detection time is short, and the leucine and the isoleucine can be perfectly separated.
Description
Technical Field
The invention belongs to the field of biochemical detection, and particularly relates to a stable underivatized detection method of free amino acid and application thereof, in particular to a high-accuracy stable underivatized detection method of free amino acid and application thereof.
Background
Amino Acids (AAs) are the core component of metabolism. They are the basic units that make up proteins, and are also regulators of gene expression and precursors to a variety of hormones and neurotransmitters. Of the 20 protein-derived AAs present in humans, most are present in human plasma at a concentration of μm. Of these 9 are essential amino acids (i.e., histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine) that must be taken into the body by balanced diet. Changes in amino acid levels have long been used as a biological indicator for disease diagnosis, e.g., metabolic fingerprinting of blood samples from cancer patients shows that AAs levels decrease significantly as disease progresses. AAs fingerprint is also an important parameter for evaluating the nutritional quality of food.
From a chemical point of view, a common feature of amino acids is the simultaneous presence of amine groups and carboxyl groups in their structure. Furthermore, because of the asymmetric α -carbon, optically active L-and D-isomers can be produced, which directly result in that they can be polar, nonpolar, acidic or basic. AAs may be positively/negatively charged or in a zwitterionic state, depending on the pH of the medium. The structure of amino acids determines the complexity of developing analytical methods on a liquid-based basis, but the function and effect of amino acids determine the necessity for accurate detection thereof.
At present, a derivatization method is mostly adopted for amino acid detection, but the reality of the detection result is doubtful due to the complexity of derivatization operation and uncontrollability of derivatization efficiency; the use of commercial derivatization kits, or the provision of accurate, precise, sensitive and reproducible results, is expensive and not suitable for routine amino acid detection assays. The quantitative analysis of amino acids by non-derivatization methods has been reported, and most of the sample pretreatment operations are performed by extracting 50% acetonitrile, which depends on the fact that the sample of the amino acid needs to be protein precipitated, but the amino acid itself is water-soluble, and only 50% acetonitrile can be selected, but the protein precipitation and the extraction efficiency of the amino acid are also compromised. Removing the difficulty of preparing amino acid samples, the amino acid itself is one of the difficulties in chromatographic separation, due to the specificity of the structure, retention separation is also achieved by adding ion pair reagents (alkyl sulfonate or perfluorocarboxylic acid, etc.) in the mobile phase of reversed phase chromatographic separation to achieve effective retention and separation of amino acids in the reversed phase chromatographic column, but the alkyl sulfonate is not volatilized and is not used for MS detection, perfluorocarboxylic acid can be considered for MS detection, but the minimum effective concentration of ion pair reagents must also be selected to limit signal suppression, as all ion pair reagents may cause contamination of the whole LC-MS system, leading to higher than normal background signals and additional noise; there are also those which are directly detected with a reverse phase column without using an ion pair reagent. However, most methods suffer from low retention of amino acids that peak before the column dead time, which is clearly unacceptable for analysis of complex matrices, and desolvation in electrospray ionization (ESI) is very difficult when RPLC analysis is performed using high water mobile phases, resulting in low MS sensitivity. In addition, the HILIC mode can analyze amino acids, can retain all amino acids, has satisfactory peak shape, is completely compatible with MS, has long balancing time, is difficult to find a proper sample diluent, mostly reports that hydrochloric acid is used as the diluent, but does not mention the stability of a method and a sample, obviously is easily volatilized with hydrochloric acid, the prepared mixed standard is more than 24 hours and cannot be stabilized, and the HILIC mode has low resolution ratio between leucine and isoleucine and poorer selectivity than the RPLC mode. Therefore, there is a need for a stable, non-derivatizing, and efficiently retained amino acid detection method that does not use ion pair reagents.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a stable non-derivatization detection method of free amino acid and application thereof, in particular to a high-accuracy and stable non-derivatization detection method of free amino acid and application thereof. The detection method provided by the invention can be used for simultaneously measuring 21 amino acids in blood plasma under the condition of not using an ion pair reagent, the sample consumption is small, the protein precipitation is complete, the chromatographic column loss caused by the sample can be reduced, the stability is high, the accuracy is high, the detection time is short, and the leucine and the isoleucine can be perfectly separated.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in one aspect, the present invention provides a method for the detection of stable free amino acids without derivatization, comprising the steps of:
mixing a sample to be detected with Deoxycholate (DOC), trichloroacetic acid and an internal standard, centrifuging, taking supernatant and sampling, carrying out liquid chromatography-mass spectrometry detection, and calculating the content of free amino acid in the sample to be detected according to a detection result and a standard curve.
According to the method, the sample to be detected is treated by adopting deoxycholate and trichloroacetic acid, the deoxycholate and trichloroacetic acid are synergistic, the protein in the sample can be effectively precipitated, the damage of the protein to a chromatographic column is obviously reduced, the internal standard and a specific liquid phase process are combined, the stability and the accuracy of detection are effectively improved, meanwhile, a derivatization method is not needed, the separation of leucine and isoleucine isomers can be ensured on the premise that an ion pair reagent is not used, and the method has the advantages of wide linear range, high recovery rate, good stability, good repeatability, high sensitivity and the like, and the reliability of qualitative and quantitative results is fully ensured.
Preferably, the sample to be measured is a blood sample.
Preferably, the free amino acids include L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-cysteine, L-leucine, L-hydroxyproline, L-tryptophan, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tyrosine, and L-valine.
The method can realize simultaneous detection of the 21 amino acids in a short time, and can ensure separation of leucine and isoleucine isomers without using ion pair reagents.
Preferably, the deoxycholate is used in the form of a solution, and the mass fraction of the deoxycholate solution is 0.13-0.17%.
Preferably, the volume ratio of the sample to be tested, deoxycholate solution and trichloroacetic acid is (8-12): (18-22): 1.
Wherein, the mass fraction of the deoxycholate solution can be 0.13%, 0.14%, 0.15%, 0.16% or 0.17%, etc., the volume ratio of the sample to be measured, the deoxycholate solution and trichloroacetic acid can be 8, 9, 10, 11 or 12, etc., the number of the sample to be measured can be 18, 19, 20, 21 or 22, etc., but not limited to the above-listed values, and other non-listed values in the above-listed value range are equally applicable.
Preferably, the internal standard comprises L-lysine-D4 hydrochloride (Lys-D4), L-glutamine-D5 (Try-D5) and L-tryptophan-D5 (Gln-D4).
Preferably, the chromatographic column of the liquid chromatography is AdvanceBio MS Spent Media.
Preferably, the liquid chromatography is carried out at 35-45 ℃, for example 35 ℃,36 ℃, 37 ℃, 38 ℃, 39 ℃,40 ℃, 41 ℃, 42 ℃, 43 ℃, 44 ℃, 45 ℃ or the like, but not limited to the values listed above, and other values not listed in the above-mentioned value ranges are equally applicable.
Preferably, the mobile phase of the liquid chromatograph comprises a mobile phase A and a mobile phase B, wherein the mobile phase A is formic acid-ammonium formate aqueous solution, and the mobile phase B is formic acid-ammonium formate acetonitrile solution.
Preferably, in the mobile phase a and the mobile phase B, the volume fraction of formic acid is independently 0.08-0.12%, and the concentration of ammonium formate is independently 8-12mM, wherein the volume fraction of formic acid may be 0.08%, 0.09%, 0.1%, 0.11%, or 0.12%, and the concentration of ammonium formate may be 8mM, 9mM, 10mM, 11mM, or 12mM, etc., but not limited to the above-listed values, and other non-listed values within the above-listed values are equally applicable.
Preferably, the acetonitrile in the aqueous acetonitrile solution in mobile phase B has a volume fraction of 93-97%, such as 93%, 94%, 95%, 96% or 97%, etc., but is not limited to the values recited above, and other values not recited in the above ranges are equally applicable.
Preferably, the elution procedure of the liquid chromatography is gradient elution, and the flow of the gradient elution is as follows:
0-3min, changing the volume fraction of the mobile phase A from 10% to 40% at uniform speed, changing the volume fraction of the mobile phase B from 90% to 60% at uniform speed, and changing the flow rate of the mobile phase to 0.45-0.55mL/min;
3-4min, the volume fraction of the mobile phase A is 40%, the volume fraction of the mobile phase B is 60%, and the flow rate of the mobile phase is 0.25-0.35mL/min;
4 th to 4.1min, the volume fraction of the mobile phase A is changed from 40% uniform velocity to 10%, the volume fraction of the mobile phase B is changed from 60% uniform velocity to 90%, and the flow rate of the mobile phase is 0.25-0.35mL/min;
4.1-6min, the volume fraction of the mobile phase A is 10%, the volume fraction of the mobile phase B is 90%, and the flow rate of the mobile phase is 0.45-0.55mL/min.
Preferably, the standard curve is prepared by a method comprising the steps of:
mixing an amino acid standard sample with hydrochloric acid to obtain a standard stock solution, diluting the standard stock solution with trichloroacetic acid solution to obtain a series of concentration gradient working solutions, diluting the working solutions with an internal standard solution, detecting according to the liquid chromatography flow, and drawing a standard curve according to the detection result.
The standard curve can effectively improve the stability of the solution by adopting trichloroacetic acid solution for dilution.
Preferably, the supernatant is diluted before injection, and the concentration of trichloroacetic acid in the diluted supernatant is 20-30mM, such as 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM or 30mM, etc., but not limited to the above-listed values, and other non-listed values within the above-listed ranges are equally applicable.
On the other hand, the invention also provides application of the detection method in amino acid content detection.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a method for detecting the underivatized free amino acid, which is characterized in that deoxycholate and trichloroacetic acid are adopted to jointly treat a sample to be detected, the deoxycholate and trichloroacetic acid are synergistic, the protein in the sample can be effectively precipitated, the damage of the protein to a chromatographic column is obviously reduced, the internal standard and a specific liquid phase process are combined, the stability and the accuracy of detection are effectively improved, meanwhile, the derivatization method is not required, the separation of leucine and isoleucine isomers can be ensured on the premise of not using an ion pair reagent, and the method has the advantages of wide linear range, high recovery rate, good stability, good repeatability, high sensitivity and the like, and the reliability of qualitative and quantitative results is fully ensured.
Drawings
FIG. 1 is a graph of the results of testing plasma samples of example 1;
FIG. 2 is a graph showing the detection results of a blank solution containing an internal standard in example 1;
FIG. 3 is a graph showing the detection results of 21 amino acid mixed labeling solutions in example 1;
FIG. 4 is a superimposed graph of individual chromatographic peaks for leucine, isoleucine and hydroxyproline in example 1;
FIG. 5 is a graph of individual peaks for Ala in example 1;
FIG. 6 is a graph of individual peaks for Asn in example 1;
FIG. 7 is a graph of individual peaks for Asp in example 1;
FIG. 8 is a graph of individual peaks for Gln in example 1;
FIG. 9 is a graph of individual peaks of Glu in example 1;
FIG. 10 is a graph of individual peaks of Gly in example 1;
FIG. 11 is a single peak plot of Lys in example 1;
FIG. 12 is a single peak plot of Ser in example 1;
FIG. 13 is a single peak plot of Thr in example 1;
FIG. 14 is a single peak plot of Arg in example 1;
FIG. 15 is a single peak plot of His in example 1;
FIG. 16 is a single peak plot of Ile in example 1;
FIG. 17 is a peak-to-peak plot of Cys alone in example 1;
FIG. 18 is a single peak plot of Leu in example 1;
FIG. 19 is a single peak plot of Hyd in example 1;
FIG. 20 is a single peak plot of Trp in example 1;
FIG. 21 is a graph of individual peaks for Met in example 1;
FIG. 22 is a single peak plot of Phe in example 1;
FIG. 23 is a single peak plot of Pro in example 1;
FIG. 24 is a single peak plot of Tyr in example 1;
FIG. 25 is a single peak plot of Val in example 1;
FIG. 26 is a graph of the individual peaks of Gln-d5 in example 1;
FIG. 27 is a single peak plot of Lys-d4 in example 1;
FIG. 28 is a graph of individual peaks of Trp-d5 in example 1;
FIG. 29 is a graph of mobile phase optimization results in conditional optimization;
FIG. 30A is a graph of sample size, flow rate, and first portion results of column Wen Youhua for condition optimization;
FIG. 30B is a graph of sample size, flow rate, and second portion results of column Wen Youhua for condition optimization;
FIG. 31 is a graph of the liquid phase results of the conditions of example 1 in condition optimization;
FIG. 32A is a graph showing the results of a first portion of the optimization of a chromatographic column and trichloroacetic acid solution in a condition optimization;
FIG. 32B is a graph showing the results of a second portion of the optimization of the chromatographic column and trichloroacetic acid solution in the condition optimization;
FIG. 33 is a graph of elution gradient optimization process results;
FIG. 34 is a graph of the results of the prior art article and the patent chromatographic condition reproduction test;
fig. 35 is a diagram of the method application detection result.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
All instruments and reagents in the following examples are as follows:
NewClassic MF MS105DU electronic balance (METTLER tolio); SBL-10DT ultrasonic constant temperature washer (Ningbo Xinzhi biotechnology Co., ltd.); centrifuge 5430R high-speed refrigerated Centrifuge (Eppendorf); QTRAP 6500 liquid chromatograph-mass spectrometer (AB SCIEX).
The 21 amino acid standard, L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-cysteine, L-leucine (leucine), L-hydroxyproline, L-tryptophan, L-lysine, L-methionine (methionine), L-phenylalanine, L-proline, L-serine, L-threonine, L-tyrosine, L-valine are all purchased from Shanghai-derived leaf Biotechnology Co., ltd. And the internal standard L-lysine-D4 hydrochloride, L-glutamine-D5, L-tryptophan-D5 are all purchased from BePure.
Example 1
This example provides a stable non-derivatization assay for free amino acids
Sample solution preparation:
accurately transferring 50 mu L of plasma to be detected, adding 91 mu L of water, mixing 100 mu L of 0.15% DOC, adding 4 mu L of 100 mu g/mL of three internal standard solution (Lys-d 4/Try-d5/Gln-d 4), mixing uniformly, performing ultrasonic treatment for 10min (5 ℃ at 40 KHz), adding 5 mu L of 10M trichloroacetic acid (TCA), mixing uniformly, freezing, standing and precipitating a sample for 10min, centrifuging at 14000rcf at 4 ℃ for 10min, taking 50 mu L of supernatant, adding 350 mu L of water, performing vortex mixing uniformly, and filtering with a biological 0.2 mu M PTFE filter membrane to obtain the plasma.
And (3) sampling the sample solution, performing liquid chromatography-mass spectrometry detection, and calculating by combining a standard curve to obtain a result, wherein the liquid chromatography-mass spectrometry parameters are as follows:
chromatographic column: advanceBio MS Spent Media (2.1X105 mm,2.7 μm), column temperature 40℃and sample loading of 1. Mu.L. Mobile phase a (0.1% formic acid 10mM ammonium formate in water) and mobile phase B (0.1% formic acid 10mM ammonium formate in 95% acetonitrile)
The gradient elution procedure was as follows:
time (min) | Flow rate (mL/min) | A% | B% |
0.0 | 0.5 | 10 | 90 |
3 | 0.3 | 40 | 60 |
4 | 0.3 | 40 | 60 |
4.1 | 0.5 | 10 | 90 |
6 | 0.5 | 10 | 90 |
Mass spectrometry conditions: AB SCIEX QTRAP 6500+, detected in positive/negative mode, gas curtain gas (CUR) of 35, collision gas (CAD) of medium level, ion spray voltage (IS) of +5500/-4500, ion source Temperature (TEM) of 550, ion source gas 1 (GS 1) of 50, ion source gas 2 (GS 2) of 50.
The mass spectral parameter information for the 21 amino acids and internal standard is as follows, with a residence time of 10ms:
wherein Hyd, ile, leu three amino acids share 132/86 ion channels; gln and Lys share 147/84 and 147/130 ion channels.
The liquid chromatography results are shown in FIG. 1 (time on the abscissa and intensity on the ordinate, and all of FIGS. 2 to 34 below are the same), the blank solution containing the internal standard, the chromatographic results of the 21 amino acid mixed standard are shown in FIGS. 2 to 3, and the superimposed graphs of the individual chromatographic peaks of leucine, isoleucine and hydroxyproline are shown in FIG. 4.
Standard curve preparation:
accurately weighing a proper amount of 21 amino acid standard substances, adding 0.1M HCl water for dissolution and volume fixation to 1 mL, and uniformly vortex mixing to obtain standard substance stock solution (-80 ℃ for storage), wherein the concentration information of the stock solution is as follows:
taking a proper amount of L-Trp-d5, L-Gln-d5 and L-Lys-d4, and preparing an internal standard stock solution (stored at 4 ℃) of 100 mug/mL by using a 5mM TCA aqueous solution;
the stock solution is diluted into 10 working solutions with different concentrations (stored at 4 ℃) by using 5mM TCA solution, and the working solution is diluted by adopting 400ng/mL of internal standard solution in equal volume to obtain a sample-injection standard curve solution, wherein the standard curve concentration information is as follows:
and then carrying out liquid phase mass spectrum detection on the standard curve solution by referring to the method, and drawing a standard curve according to the detection result, wherein the result is as follows:
the individual peak patterns of the 21 amino acids and the internal standard are shown in FIGS. 5-28. The results show that 21 amino acids have good linearity in the linear range, the standard curve range is more than C2-C9, and the correlation coefficient is more than 0.99.
And (3) methodological verification:
stability of
The experimental method comprises the following steps: 3 samples of the sample solution to be tested are respectively prepared for each concentration by adopting low, medium and high concentration quality control, and the stability of the sample is evaluated for 84 hours by using 9 samples and 63 measurement results, wherein the method comprises the following steps: 0,6, 24, 36, 48, 72, 84h, see table 1.
3 samples of the test solution are prepared for each concentration by adopting low, medium and high concentration quality control, and the storage stability is evaluated by measuring the total of 63 samples, wherein the method comprises the following steps: the stability was calculated by analysis according to established analytical methods of LCMS quantification by placing at 20 ℃ for 36h and 48h, at 4 ℃ for 36h and 48h, and at-20 ℃ for 36h, 48h and 72h, as shown in table 2.
Experimental results: the stability accuracy of 21 amino acids at 84h is 87.2-107.4%, and RSD is less than 15%. The stability accuracy of the 21 amino acids under different storage conditions is between 87.9 and 109.7 percent, and the RSD is less than 15 percent.
Table 1 stability test for 84h
/>
TABLE 2 storage stability experiments
/>
Intra-batch and inter-batch precision
The experimental method comprises the following steps: the precision adopts 3 different concentrations (low, medium and high quality control concentrations), 5 parts of test sample solutions are respectively prepared for each concentration, 15 measurement results are used for evaluating the precision in the batch, three analysis batches including 3 different concentrations (low, medium and high quality control concentrations) are collected within 3 days, 5 parts of test sample solutions are respectively prepared for each concentration, and 15 measurement results are used for evaluating the precision between batches. The peak areas were recorded by separate injection chromatography-mass spectrometry, and the content and relative standard deviation of 21 amino acids were calculated, see table below.
Experimental results: the daily precision of the amino acids except Arg reaches 124.5%, the daily precision of the rest amino acids is 86.4-113.1%, and the RSD values are all less than 15%.
/>
Accuracy of
The experimental method comprises the following steps: the accuracy inspection of the method is carried out by adopting a recovery rate method, taking 25 mu L of bovine serum, adding a proper amount of water, uniformly mixing 100 mu L of 0.15% DOC, adding 4 mu L of 100 mu g/mL of three internal standard solution (Lys-d 4/Try-d5/Gln-d 4), adding 10/20/30 mu L (low, medium and high concentration) of standard solution respectively, uniformly mixing, performing ultrasonic treatment for 10min (5 ℃ and 40 KHz), adding 5 mu L of 10M trichloroacetic acid (TCA), uniformly mixing, finally obtaining a sample solution with the volume of 250 mu L, freezing, standing and precipitating the sample for 10min, centrifuging for 10min at the temperature of 14000rcf at the temperature of 4 ℃, taking 50 mu L of supernatant, adding 350 mu L of water, uniformly vortex, and filtering a biological PTFE filter membrane with the thickness of 0.2 mu M. 5 parts of the sample solutions were prepared for each concentration and the recovery rate was evaluated using 15 measurement results.
Precisely sucking 1 μl of each of the control solution and the sample solution, and measuring with injection chromatography-mass spectrometry according to established chromatographic conditions, and calculating recovery rate according to the following formula:
percent recovery = (measured value of measured object in the labeled sample-amount of measured object contained in the sample taken)/amount of reference substance added x 100%. The results are shown in the following table.
/>
/>
Condition optimization:
the conditions in example 1 were replaced with the same ones including the type and concentration of mobile phase, the amount of sample introduced, the flow rate of mobile phase, the column temperature, the type of chromatographic column, and the concentration and solvent of trichloroacetic acid solution for dilution of the stock solution of standard, respectively, as shown in FIGS. 29 to 32 (changing conditions are shown in the drawing, wherein FIG. 31 is the conditions of example 1)
From FIG. 29 (A chromatographic conditions: mobile phase A (0.1% aqueous formic acid solution) mobile phase B (0.1% aqueous formic acid acetonitrile solution), B chromatographic conditions: mobile phase A (0.1% aqueous formic acid 10mM ammonium formate-95% aqueous solution) mobile phase B (0.1% formic acid 10mM ammonium formate-95% acetonitrile solution), C chromatographic conditions: mobile phase A (0.1% aqueous formic acid 10mM ammonium formate solution) mobile phase B (0.1% formic acid 10mM ammonium formate-95% acetonitrile solution)), it was found that the addition of ammonium formate in the mobile phase significantly improved the separation of leucine from isoleucine and increased the retention of amino acids as a whole; the column temperature is examined at 35, 40 and 45 ℃, the flow rate is examined at 0.45, 0.5 and 0.55mL/min, the sample injection amount is examined at 1 and 2 mu L, the comparison chart in the optimization process of different chromatographic conditions is shown in figure 30A (the sample injection amount of the A chromatographic condition is adjusted to 2 mu L, the default sample injection amount of the B chromatographic condition is adjusted to 1 mu L, the flow rate is adjusted to 0.55mL/min, the C chromatographic condition is adjusted to 1 mu L, the flow rate is adjusted to 0.55 mL/min), the sample injection amount of the B chromatographic condition is 1 mu L, the default flow rate is adjusted to 0.50mL/min, the column temperature is adjusted to 35 ℃, and the influence of the three parameters on amino acid detection is not obvious; for concentration studies of the chromatographic columns and trichloroacetic acid solutions, a comparison of Waters BEH Amide (2.1X100 mm,1.7 μm) with AdvanceBio MS Spent Media (2.1X105 mm,2.7 μm), i.e., amide and AdvanceBio chromatographic columns, was shown in FIG. 32A (both of which were Amide chromatographic columns, A was prepared by diluting 10mM TCA50% acetonitrile aqueous solution, B was prepared by diluting 5mM TCA50% acetonitrile aqueous solution), 32B (A was Amide chromatographic column, B was AdvanceBio chromatographic column, and example 1 conditions were adopted), and it was apparent that AdvanceBio MS Spent Media chromatographic columns were superior to Waters BEH Amide in terms of retention and peak pattern under the same conditions, so AdvanceBio MS Spent Media chromatographic columns were selected as the chromatographic columns used in the present invention.
Elution procedure investigation:
the elution program of the invention is mainly optimized for the separation of leucine and isoleucine and the overall retention degree of amino acid, and is optimized for 23 times in total, and the elution gradient in the three optimization processes are listed below as shown in figure 33 (the elution condition flow rate of A is 0.3mL/min, the elution gradient is 0/3/4/4.1/6min, and the elution gradient corresponds to mobile phase B80/60/60/90/90%; the flow rate of the elution condition of B is 0.35mL/min, the elution gradient is 0/3/4/4.1/6min, corresponding to mobile phase B90/60/60/90/90%, the elution gradient of C is 0/1/3/4/4.1/6min, corresponding to mobile phase B90/90/60/60/90/90%, the corresponding flow rate is 0.5/0.5/0.3/0.5/0.5 mL/min, and the chromatogram reproduced according to the article and the existing patent chromatographic condition is shown in FIG. 34 (A is a chromatographic condition adopting patent application chromatographic column Waters BEH Amide (2.1×100mm,1.7 μm) with reference to publication number CN 114019034A), B is a chromatographic condition detection result mentioned in article about free amino acid detection in article No. Journal of Chromatography A by Bo Yuan et al, no. 2021:3267-high performance liquid chromatography tandem mass spectrometry and interactive machine learning, C is a chromatographic condition detection result of the present patent, and the chromatographic column is a mixture of 21 amino acid standard samples detected by above three detection methods, the reproduction chromatogram of the patent shows that the separation of the amino acid is obviously problematic for 6-9 min, the peak type is extremely bad, the basic line of a large section for 10-14 min is unreasonable to the gradient design, the reproduction chromatogram of the article shows that the overall peak type is good, but the distribution of the overall peak is back, and the leucine and the isoleucine do not reach the separation requirement.
Stability investigation of hydrochloric acid dilution standard curve
The 5mM TCA of example 1 was replaced with 10mM hydrochloric acid 50% acetonitrile and diluted to prepare standard curve whose linearity and range and stability data are as follows:
linearity and range
Because the standard curve range of hydrochloric acid dilution is narrow, the stability of low concentration and medium concentration quality control detection is poor, so only the stability data of high concentration quality control 12, 24 and 48h respectively are shown as follows, wherein Cys, gln, hyd, thr, trp, tyr shows instability at 24 h:
/>
sample preparation stability investigation
After thawing the plasma sample, sub-packaging a plurality of 50 muL to 1.5mL EP tubes, cryopreserving at-20 ℃, designing and preparing a plurality of samples, simultaneously storing at Room Temperature (RT), 4 ℃ and-20 ℃, respectively measuring 0, 36, 48 and 72h data, calculating stability, wherein the result that the data at-20 ℃ are all abnormally high, and freeze thawing out is possible, or even mixing is needed after freeze thawing, the stability of RT 48h and the stability data at 4 ℃ 48 and 72h are as follows, and in addition, sample preparation detection is carried out on the sub-packaged and cryopreserved samples on the first day, the second day and the twenty-fifth day respectively, wherein the stability data are as follows, and only the stability of Lys data is insufficient.
/>
Investigation of protein precipitation
The patent designs A/B/C/D/E/F/G/H experiments according to the protein precipitation step of the sample, and proves the advantages of the protein precipitation method in the sample solution preparation method, wherein a/B is a parallel experiment, and the conditions corresponding to the experiments are as follows: a, weighing and recording an EP tube, accurately transferring 50 mu L of plasma to be measured to the EP tube, adding 91 mu L of water, mixing 100 mu L of 0.15% DOC, adding 4 mu L of 100 mu g/mL of a three-internal standard solution (Lys-d 4/Try-d5/Gln-d 4), mixing uniformly, performing ultrasonic treatment for 10min (5 ℃ at 40 KHz), adding 5 mu L of 10M trichloroacetic acid (TCA), mixing uniformly, freezing and standing a sample, precipitating for 10min, centrifuging for 10min at 14000rcf at 4 ℃, completely removing the supernatant, weighing the EP tube, adding the precipitation weight, and calculating to obtain the precipitation weight; b experiment, based on A experiment, adding 91 μL water to 195 μL water, and not adding 0.15% DOC; c, on the basis of the A experiment, adding 91 mu L of water to 96 mu L of water, and not adding 10M trichloroacetic acid; d, based on the A experiment, adding 91 mu L of water to adjust to 150 mu L of acetonitrile, and not adding 0.15% DOC and 10M trichloroacetic acid; e, based on the A experiment, adding 91 mu L of water to adjust to 200 mu L of 50% acetonitrile, and not adding 0.15% DOC and 10M trichloroacetic acid; f, based on the A experiment, adding 91 mu L of water to 250 mu L of methanol, and not adding 0.15% DOC and 10M trichloroacetic acid; g, on the basis of the experiment A, transferring 50 mu L of plasma to be detected to an EP tube, adding 91 mu L of water to adjust to transfer 25 mu L of plasma to be detected to the EP tube, and adding 116 mu L of water; h experiment, based on experiment G, 116 μl of water was adjusted to 216 μl of water, and 0.15% doc was not added; experimental results show that 1) no trichloroacetic acid is added to precipitate protein; 2) The protein precipitation amount of the patent is more than three times of acetonitrile and five times of methanol to precipitate protein; 3) The addition of 0.15% DOC increases the amount of protein precipitated when the protein concentration is not high.
Experimental conditions | Amount of protein precipitate (mg) |
A-a | 34.47 |
A-b | 33.28 |
B-a | 33.74 |
B-b | 33.99 |
C-a | 0 |
C-b | 0 |
D-a | 20.13 |
D-b | 19.49 |
E-a | 22.33 |
E-b | 18.57 |
F-a | 29.26 |
F-b | 27.35 |
G-a | 22.24 |
G-b | 22.95 |
H-a | 17.77 |
H-b | 18.98 |
Method application
The method of example 1 is used for measuring endogenous free amino acids in human, pig, cow, mouse and rat plasma, and the result is shown in figure 35, and it can be seen that the method of the invention realizes simultaneous measurement of different kinds of free amino acids in plasma by pretreatment of samples and selection of UPLC MS/MS measurement conditions, and the linear range, quantitative limit, stability, precision and accuracy of the method meet analysis requirements, and the method is simple and convenient and has high analysis efficiency.
The applicant states that the present invention is illustrated by the above examples as a method for the detection of the undenaturation of stable free amino acids and its use, but the present invention is not limited to the above examples, i.e. it is not meant that the present invention must be carried out in dependence on the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (10)
1. A method for the detection of stable free amino acids without derivatization, characterized in that it comprises the steps of:
mixing a sample to be detected with deoxycholate, trichloroacetic acid and an internal standard, centrifuging, taking supernatant, sampling, detecting by liquid chromatography-mass spectrometry, and calculating the content of free amino acid in the sample to be detected according to the detection result and a standard curve.
2. The method according to claim 1, wherein the sample to be tested is a blood sample;
preferably, the free amino acids include L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-cysteine, L-leucine, L-hydroxyproline, L-tryptophan, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tyrosine, and L-valine.
3. The detection method according to claim 1 or 2, wherein the deoxycholate is used in the form of a solution, and the mass fraction of the deoxycholate solution is 0.13-0.17%;
preferably, the volume ratio of the sample to be tested, deoxycholate solution and trichloroacetic acid is (8-12): (18-22): 1.
4. A detection method according to any one of claims 1-3, wherein the internal standard comprises L-lysine-D4 hydrochloride, L-glutamine-D5 and L-tryptophan-D5.
5. The method according to any one of claims 1 to 4, wherein the column of the liquid chromatograph is AdvanceBio MS Spent Media;
preferably, the liquid chromatography is carried out at a temperature of 35-45 ℃.
6. The method according to any one of claims 1 to 5, wherein the mobile phase of the liquid chromatograph comprises a mobile phase a and a mobile phase B, the mobile phase a being an aqueous formic acid-ammonium formate solution, the mobile phase B being an aqueous formic acid-ammonium formate acetonitrile solution;
preferably, in the mobile phase A and the mobile phase B, the volume fraction of formic acid is independently 0.08-0.12%, and the concentration of ammonium formate is independently 8-12mM;
preferably, the acetonitrile is present in the aqueous acetonitrile solution in mobile phase B in a volume fraction of 93-97%.
7. The method according to claim 6, wherein the elution procedure of the liquid chromatography is gradient elution, and the flow of the gradient elution is as follows:
0-3min, changing the volume fraction of the mobile phase A from 10% to 40% at uniform speed, changing the volume fraction of the mobile phase B from 90% to 60% at uniform speed, and changing the flow rate of the mobile phase to 0.45-0.55mL/min;
3-4min, the volume fraction of the mobile phase A is 40%, the volume fraction of the mobile phase B is 60%, and the flow rate of the mobile phase is 0.25-0.35mL/min;
4 th to 4.1min, the volume fraction of the mobile phase A is changed from 40% uniform velocity to 10%, the volume fraction of the mobile phase B is changed from 60% uniform velocity to 90%, and the flow rate of the mobile phase is 0.25-0.35mL/min;
4.1-6min, the volume fraction of the mobile phase A is 10%, the volume fraction of the mobile phase B is 90%, and the flow rate of the mobile phase is 0.45-0.55mL/min.
8. The method of any one of claims 1-7, wherein the standard curve is prepared by a method comprising the steps of:
mixing an amino acid standard sample with hydrochloric acid to obtain a standard stock solution, diluting the standard stock solution with trichloroacetic acid solution to obtain a series of concentration gradient working solutions, diluting the working solutions with an internal standard solution, detecting according to the liquid chromatography flow of any one of claims 1-7, and drawing a standard curve according to the detection result.
9. The method according to claim 8, wherein the supernatant is diluted before sample injection, and the concentration of trichloroacetic acid in the diluted supernatant is 20-30mM.
10. Use of the detection method according to any one of claims 1-9 in the detection of amino acid content.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310972108.6A CN117030878A (en) | 2023-08-03 | 2023-08-03 | Stable free amino acid underivatization detection method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310972108.6A CN117030878A (en) | 2023-08-03 | 2023-08-03 | Stable free amino acid underivatization detection method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117030878A true CN117030878A (en) | 2023-11-10 |
Family
ID=88636543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310972108.6A Pending CN117030878A (en) | 2023-08-03 | 2023-08-03 | Stable free amino acid underivatization detection method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117030878A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118010453A (en) * | 2024-04-08 | 2024-05-10 | 四川旅游学院 | Free amino acid detection processing device and method suitable for meat samples |
-
2023
- 2023-08-03 CN CN202310972108.6A patent/CN117030878A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118010453A (en) * | 2024-04-08 | 2024-05-10 | 四川旅游学院 | Free amino acid detection processing device and method suitable for meat samples |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7399214B2 (en) | Amino acid analysis in body fluids by liquid chromatography mass spectrometry | |
US8945933B2 (en) | Liquid chromatography-mass spectrometry methods for multiplexed detection and quantitation of free amino acids | |
EP1750126B1 (en) | Method and apparatus for analyzing aminofunctional compound | |
Servais et al. | Capillary electrophoresis‐mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery | |
CN114236025B (en) | Method for determining 43 amino acids without ion pair reagent and non-derivatization | |
CN111189939A (en) | Method for detecting endogenous free amino acids of plants by using ultra-high performance liquid chromatography-tandem mass spectrometry | |
CN117030878A (en) | Stable free amino acid underivatization detection method and application thereof | |
CN111679028B (en) | High performance liquid chromatography tandem mass spectrometry detection method for four peptides in cosmetics | |
US7700364B2 (en) | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry | |
Zhu et al. | A simultaneously quantitative profiling method for 40 endogenous amino acids and derivatives in cell lines using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry | |
Balest et al. | Ultra-trace levels analysis of microcystins and nodularin in surface water by on-line solid-phase extraction with high-performance liquid chromatography tandem mass spectrometry | |
CN113419007B (en) | Method for detecting target amino acid and creatinine in sample and detection kit thereof | |
CN111307975A (en) | Detection method of 8 amino acids in mouse cortex | |
Li et al. | Simultaneous determination of aminoglycoside residues in food animal muscles by mixed-mode liquid chromatography-tandem mass spectrometry | |
Giordano et al. | Quantification of underivatized amino acids on dry blood spot, plasma, and urine by HPLC-ESI-MS/MS | |
Du et al. | Analysis of amino acids in human tears by hydrophilic interaction liquid chromatography and quadrupole orbitrap mass spectrometry | |
CN113009030A (en) | Amino acid high-throughput target detection method and application thereof | |
CN114624338A (en) | Method for quantitatively analyzing free amino acids in biological sample by using liquid chromatography-tandem mass spectrometry | |
KR20210117268A (en) | High-Speed Sample Workflow for LC-MS-Based HBA1C Instrumentation | |
CN117517541B (en) | Method for measuring concentration of glycylglycine in blood plasma | |
CN114441681B (en) | Method for determining 20 free amino acids and L-hydroxyproline in special medical formula food | |
CN117969717A (en) | Method for detecting total content of characteristic tripeptides in collagen peptide | |
CN114935609A (en) | High-throughput target detection method for biological sample polyamine and related metabolites | |
CN117147868A (en) | Metalloprotein and method for detecting protein capable of forming metalloprotease | |
Csapó et al. | Separation and determination of the amino acids by ion exchange column chromatography applying post-column derivatization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |